1. Aptamers as Delivery Agents of siRNA and Chimeric Formulations for the Treatment of Cancer
- Author
-
Sotiris Missailidis, Dinis Ano Bom Ap, Bonacossa de Almeida Ce, Silva D, and da Costa Neves Pc
- Subjects
0303 health sciences ,Small interfering RNA ,business.industry ,Aptamer ,aptamers ,Pharmaceutical Science ,Cancer ,02 engineering and technology ,Review ,021001 nanoscience & nanotechnology ,medicine.disease ,03 medical and health sciences ,siRNA ,Cancer research ,Medicine ,Gene silencing ,cancer ,nanoparticles ,0210 nano-technology ,business ,Cytotoxicity ,030304 developmental biology - Abstract
Both aptamers and siRNA technologies have now reached maturity, and both have been validated with a product in the market. However, although pegaptanib reached the market some time ago, there has been a slow process for new aptamers to follow. Today, some 40 aptamers are in the market, but many in combination with siRNAs, in the form of specific delivery agents. This combination offers the potential to explore the high affinity and specificity of aptamers, the silencing power of siRNA, and, at times, the cytotoxicity of chemotherapy molecules in powerful combinations that promise to delivery new and potent therapies. In this review, we report new developments in the field, following up from our previous work, more specifically on the use of aptamers as delivery agents of siRNA in nanoparticle formulations, alone or in combination with chemotherapy, for the treatment of cancer.
- Published
- 2019